Obsidian Therapeutics, Inc. (OBX)
10.70
+1.10
(+11.46%)
USD |
NASDAQ |
Nov 06, 09:56
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.187M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | 0.0661 |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0959 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Obsidian Therapeutics Inc. engages in developing cell and gene therapies, particularly for the treatment of solid tumors and cancer. The company was founded on September 29, 2015 and is headquartered in Malvern, PA. |
| URL | http://obsidiantx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Pennsylvania |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Obsidian Therapeutics Inc. engages in developing cell and gene therapies, particularly for the treatment of solid tumors and cancer. The company was founded on September 29, 2015 and is headquartered in Malvern, PA. |
| URL | http://obsidiantx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Pennsylvania |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |